Clinical trials in diffuse large B cell lymphoma

The table below shows a list of The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.

If you would like to know how to access our trials please click here.

 

 

Trial Name

 

Description

 

Click the link for more information (external page)

 

ACCEPT

 

A phase 1b/2 study of acalabrutinib with R-CHOP chemotherapy

Suitable for patients who haven’t yet received any treatment

 

 

 

BI 1206 CRUK CD32b

 

Phase 1/2a study looking at blocking the CD32b protein with the antibody BI 1206.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

C34004

 

Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

ARGO

 

A phase II study of Atezolizumab with Rituximab, Gemcitabine and Oxaliplatin

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

IELSG37

 

A phase 3 study to find out if radiotherapy can be safely omitted in people with primary mediastinal large B-cell lymphoma who are PET negative after chemotherapy.

Suitable for patients who haven't yet received any treatment.

 

 

 

INCA

 

Phase 2 trial comparing inotuzumab ozogamicin and gemcitabine with R-CVP in patients unsuitable for R-CHOP.

Suitable for patients who haven’t yet received any treatment.

 

 

 

JAVELIN DLBCL

 

A phase 1/3 trial testing a new drug avelumab.

Suitable for patients with lymphoma which has come back after previous treatment.

 

 

 

LYMRIT 37 05

 

Phase 1 study of the antibody Betalutin® which targets the CD37 antigen.

Suitable for patients with lymphoma which has come back after previous treatment.

 

 

 

PCYC-1123

 

Phase 1b/2 study of ibrutinib, lenalidomide and rituxumab

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

MaPLe

 

Non-medicinal (observational) study involving molecular profiling on patients with suspected or confirmed DLBCL or grade 3b follicular lymphoma

 

 

 

RiVa

 

Phase 2 trial testing the combination of rituximab and varlilumab in people with high grade and low grade lymphomas

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

Please note, we update this page fortnightly

With special thanks to the following organisations:

;